Therapy areas
Helping your patients make the right choice
With rising abortion rates, particularly among all ages 25 and above, the largest increase are amongst women aged 30. Therefore, there is a clear need to offer the most effective contraceptive methods.1 In a quantitative survey of over 430 women and their experiences of unintended pregnancy and abortion, over half were using contraception at the time they became pregnant.2 Long-acting methods can be the most effective form of contraception because they do not rely on user compliance.3
Here you will find resources to guide conversations with your patients, helping to identify which is the most suitable contraception for them.
- Department of Health Abortion statistics England and Wales 2019 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/891405/abortion-statistics-commentary-2019.pdf. Last accessed: December 2020. Return to content
- Bury, Louise; Hoggart, Lesley and Newton, Victoria Louise (2015). Young women’s experiences of unintended pregnancy and abortion: key findings. The Open University, Milton Keynes, UK. Available at: https://oro.open.ac.uk/45138/1/MSI_key-findings_10-15_email.pdf. Last accessed: December 2020. Return to content
- Cristobal I, et al. Eur J Obstet Gynecol Reprod Biol 2015;190:58–64. Return to content
Pill compliance is a common struggle for women1
For every 100 women that choose to take the pill this year, nine could become pregnant due to missed-pill moments.2 Long-acting methods such as intrauterine systems (IUS) offer birth control with the highest available efficacy and are one of the most effective contraceptive methods because their effectiveness is independent of user compliance.3
- Merki-Feld GS, et al. Eur J Contracep Reprod Health Care 2018:183–193. Return to content
- NHS. How effective is contraception at preventing pregnancy? - Your contraception guide [online]. Updated 30 June 2017. Available from: https://www.nhs.uk/conditions/contraception/how-effective-contraception/ [Last accessed: February 2021]. Return to content
- Cristobal I, et al. Eur J Obstet Gynecol Reprod Biol 2015;190:58–64. Return to content
Choose an IUS that best meets her needs
| Jaydess®▼1 13.5 mg intrauterine delivery system (levonorgestrel) |
Kyleena®2 19.5 mg intrauterine delivery system (levonorgestrel) |
Mirena®3 52 mg intrauterine delivery system (levonorgestrel) |
|
|---|---|---|---|
| Indication | Contraception for up to 3 years | Contraception for up to 5 years | Contraception for up to 5 years Treatement of HMB for up to 5 years endometrial protection during HRT for 4 years |
| Pearl Index (efficacy) | Year 1:0.41 3-years: 0:33 |
Year 1: 0.16 5-years: 0.29 |
Year 1: 0.2 Years 5: 0.144 |
| Contraceptive failure rate | 0.4% at 1 year 0.9% over 3 years |
0.2% at 1 year 1.4% over 5 years |
0.2% at 1 year 0.7% over 5 years |
| Total levonorgestrel (LNG) content (mg) | 13.5 | 19.5 | 52 |
| Average in vivo LNG release rate over the first year of use | 8 μg/24 hours | 12.6 μg/24 hours2 | 20 μg/24 hours |
| % of women experiencing amenorrhoea and infrequent bleeding at 1 year post insertion | Amenorrhoea: 6% infrequent bleeding: 20% |
Amenorrhoea: 12% infrequent bleeding: 26% |
Amenorrhoea: 16% infrequent bleeding: 57% |
| T-frame size (mm) | 28 × 30 | 28 × 30 | 32 × 324 |
| Placement tube diameter size (mm) | 3.8 | 3.8 | 4.4 |
| Colour of monofilament threads | Brown | Blue | Brown |
| Differentiator in imaging techniques:silver ring | Improved visibility on ultrasound | Improved visibility on ultrasound | - |
- Bayer Plc. Jaydess®▼13.5 mg intrauterine delivery system (levonorgestrel): Summary of Product Characteristics [online]. Updated 10 July 2020. Available from: https://www.medicines.org.uk/emc/product/5297/smpc [Last accessed: December 2020]. Return to content
- Bayer Plc. Kyleena® 19.5 mg intrauterine delivery system (levonorgestrel): Summary of Product Characteristics [online]. Updated 10 July 2020. Available from: https://www.medicines.org.uk/emc/product/769/smpc [Last accessed: December 2020]. Return to content
- Bayer Plc. Mirena® 52 mg intrauterine delivery system (levonorgestrel): Summary of Product Characteristics [online]. Updated 05 Jan 2021. Available from: https://www.medicines.org.uk/emc/product/1132/smpc [Last accessed: January 2021]. Return to content
- Bayer Plc. Mirena® 52 mg intrauterine delivery system (levonorgestrel): Product Information. Bayer Australia. Updated 11 October 2018. [Last accessed: December 2020]. Return to content
Recommendations
Reporting adverse events and quality complaints
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.
If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 01182063500 or email: pvuk@bayer.com
Further information is available on the “contact” tab at www.bayer.co.uk.
